🔎 Trials Near Me

Avaleht › Ülekaalulisus › Nevada

Ülekaalulisus kliinilised uuringud osariigis Nevada

24 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid osariigis Nevada.

Linnad osariigis Nevada

Ametlik uuringutekst (inglise keeles)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Vector Clinical Trials /ID# 282265, Las Vegas
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT07752979

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Palm Research Center Inc., Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT07720271

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • M3 Wake Research - Las Vegas Cimarron, Las Vegas
  • Renascor Clinical Research, Reno
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT07794579

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  • Research Site, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07776509

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Palm Research Center Tenaya, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Excel Clinical Research, Las Vegas
  • Vector Clinical Trials, Las Vegas
VärbamineFaas 3
Vanused 45–99 · Kõik sood · Uuendatud 22. sept 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • AMR Clinical, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07321886

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Las Vegas Medical Research, Las Vegas
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 22. sept 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743450

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Las Vegas
VärbamineFaas 3Terved vabatahtlikud oodatud
Vanused 18–79 · Kõik sood · Uuendatud 11. sept 2026 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  • Jubilee Clinical Research, Inc., Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT07770841

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Las Vegas Medical Research, Las Vegas
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 8. sept 2026 · NCT06143956

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • Vector Clinical Trials, Las Vegas
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 8. sept 2026 · NCT07215559

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  • Skin Cancer and Dermatology Institute - Reno, Reno
VärbamineFaas 4
Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. sept 2026 · NCT06857942

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Palm Research Center Inc, Las Vegas
  • Vector Clinical Trials, Las Vegas
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 3. sept 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Palm Research Center Inc, Las Vegas
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 3. sept 2026 · NCT07684144

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Excel Clinical Research, Las Vegas
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 27. aug 2026 · NCT07575399

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

  • University of Nevada, Las Vegas, Las Vegas
VärbamineTerved vabatahtlikud oodatud
Vanused 21–74 · Kõik sood · Uuendatud 27. aug 2026 · NCT07566325

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Las Vegas
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. aug 2026 · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Las Vegas
VärbamineFaas 3
Vanused 18–79 · Kõik sood · Uuendatud 10. aug 2026 · NCT07654361

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

  • Corxel Investigational site, Las Vegas
VärbamineFaas 1
Vanused 18–55 · Naised · Uuendatud 17. juuni 2026 · NCT07652047

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.